Optimizing conventional medical therapies in inflammatory bowel disease in 2014.
Curr Drug Targets
; 15(11): 1002-10, 2014.
Article
en En
| MEDLINE
| ID: mdl-25219568
ABSTRACT
Goals of therapy for inflammatory bowel disease have advanced beyond symptom control to the normalization of biomarkers of inflammation, and mucosal healing in particular, with the expectation that this will change the natural history of these diseases. Concurrent with higher treatment expectations has come an expanded therapeutic armamentarium to achieve these goals, and a greater ability to optimize each therapeutic class to maximize therapeutic benefits and minimize unnecessary treatment failures. In addition to these advances has come the evolution of therapeutic drug monitoring which is increasingly being utilized to optimize the use of immunomodulators and biologic therapies in particular. This review will outline the principals of optimization of the conventional medical therapies available to the clinician today.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedades Inflamatorias del Intestino
/
Monitoreo de Drogas
Límite:
Humans
Idioma:
En
Revista:
Curr Drug Targets
Asunto de la revista:
TERAPIA POR MEDICAMENTOS
Año:
2014
Tipo del documento:
Article